ASH 2022 Phase 3 VITAL Study: Survival Benefit of Birtamimab in Mayo Stage IV AL Amyloidosis Consistent After Adjustment for Key Baseline Variables

78 views
December 19, 2022
Comments 0
Login to view comments. Click here to Login